JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction
International Journal of Biological Sciences · 2025
DOI: 10.7150/ijbs.113726 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2025. Verfasst von Kyoung-Seok Oh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Tankyrases, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
PARP inhibitors have demonstrated antitumor efficacy in solid tumors, including pancreatic ductal adenocarcinoma (PDAC) characterized by homologous recombination deficiency (HRD). The definition of HRD and other potential biomarkers should be further evaluated using PARP inhibitors. JPI-547 is a novel dual inhibitor targeting PARP1/2 and Tankyrase1/2. Herein, we demonstrate the potent antitumor activity of JPI-547 against BRCA2-/- PDAC cells. JPI-547 outperformed most PARP inhibitors, with a half-maximal inhibitory concentration approximately 10-fold lower than that of olaparib. JPI-547 efficiently trapped PARP1 on the chromatin, disrupted poly-ADP-ribosylation, induced G2/M phase arrest, and triggered apoptosis in PDAC cells. In addition to HRD, we identified Wnt addiction as a predictive factor for JPI-547 activity. PDAC cells reliant on Wnt signaling due to pathogenic RNF43 mutations showed increased susceptibility to JPI-547 without altering homologous recombination repair efficiency. JPI-547 disrupts the Wnt/β-catenin pathway in RNF43-mutated cells and inhibits the oncogenic YAP pathway, highlighting its multifaceted therapeutic potential in PDAC with HRD or Wnt-addiction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.
- Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul 03080, Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Korea.
Zitieren
APA
Oh, K. S., Nam, A. R., Bang, J. H., Jeong, Y., Choo, S. Y., Kim, H. J., Lee, S. I., Kim, J. M., Yoon, J., Kim, T. Y., & Oh, D. Y. (2025). JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.113726
Vancouver
Oh KS, Nam AR, Bang JH, Jeong Y, Choo SY, Kim HJ, et al. JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction. International Journal of Biological Sciences. 2025. doi:10.7150/ijbs.113726
BibTeX
@article{Oh2025,
author = {Oh, Kyoung-Seok and Nam, Ah-Rong and Bang, Ju-Hee and Jeong, Yoojin and Choo, Sea Young and Kim, Hyo Jung and Lee, Su In and Kim, Jae-Min and Yoon, Jeesun and Kim, Tae-Yong and Oh, Do-Youn},
title = {JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction},
journal = {International Journal of Biological Sciences},
year = {2025},
doi = {10.7150/ijbs.113726}
}
EUVIMED